Of these, IL-6 is a target for a therapy that is in phase II clinical trials to treat severe asthma (clazakizumab), and IL-4R is a target for dupilumab, which has been tested in clinical trials for uncontrolled severe asthmatics.67 This evidence concerns the gene IL4R and asthma.